Evidence map›Paper›PMID 39896961›Full record

ArticleThe Lancet regional health. Europe2025

Features of myositis and myasthenia gravis in patients treated with immune checkpoint inhibitors: a multicentric, retrospective cohort study.

Lotta Plomp, Hortense Chassepot, Dimitri Psimaras, Thierry Maisonobe, Eric Mensi, Sarah Leonard-Louis, Isabelle Plu, Antoine Rozes, Florence Tubach, Mehdi Touat and 21 more

Abstract read
In one paragraph

Article in The Lancet regional health. Europe, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Lotta PlompSorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Clinical Immunology and Internal Medicine, INSERM U974, Paris, France.
Hortense ChassepotUniversity of Picardie Jules Vernes - Amiens Picardie University Hospital, Department of Clinical Immunology and Internal Medicine, Amiens, France.
Dimitri PsimarasSorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Neurology, INSERM U974, Paris, France.
Thierry MaisonobeSorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Clinical Neurophysiology, INSERM U974, Paris, France.
Eric MensiUniversity of Rennes - Rennes University Hospital, Department of Clinical Immunology and Internal Medicine, Rennes, France.
Sarah Leonard-LouisSorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Neuropathology, INSERM U974, Paris, France.
Isabelle PluSorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Neuropathology, INSERM U974, Paris, France.
Antoine RozesSorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Center of Pharmacoepidemiology (Cephepi), INSERM, CIC-1901, Paris, France.
Florence TubachSorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Center of Pharmacoepidemiology (Cephepi), INSERM, CIC-1901, Paris, France.
Mehdi TouatSorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Neurology, INSERM U974, Paris, France.
Celine AnquetilSorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Clinical Immunology and Internal Medicine, INSERM U974, Paris, France.
Nadege WesnerSorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Clinical Immunology and Internal Medicine, INSERM U974, Paris, France.
Nicolas ChamptiauxSorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Clinical Immunology and Internal Medicine, INSERM U974, Paris, France.
Aude RigoletSorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Clinical Immunology and Internal Medicine, INSERM U974, Paris, France.
Sophie DemeretSorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Neurology, INSERM U974, Paris, France.
Nicolas WeissSorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Neurology, INSERM U974, Paris, France.
Marie-Alexandra AlyanakianParis-Cité University - AP-HP and INEM, Necker-Enfants Malades Hospital, Laboratory of Immunology, Paris, France.
Rozen Le PanseSorbonne University - Center of Research in Myology, Institute of Myology, INSERM U974, Paris, France.
Frédérique TruffaultSorbonne University - Center of Research in Myology, Institute of Myology, INSERM U974, Paris, France.
Marie-Agnès Dragon-DureyParis-Cité University - AP-HP, Georges Pompidou European Hospital, Laboratory of Immunology, Paris, France.
Lucienne ChatenoudParis-Cité University - AP-HP and INEM, Necker-Enfants Malades Hospital, Laboratory of Immunology, Paris, France.
Baptiste AbbarSorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Oncology, INSERM, Paris, France.
Marie-Claire BretagneSorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Pharmacology, INSERM, Paris, France.
Adrien ProcureurSorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Pharmacology, INSERM, Paris, France.
Thomas SimilowskiSorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Pneumology, INSERM, Paris, France.
Capucine Morelot-PanziniSorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Pneumology, INSERM, Paris, France.
Martin DresSorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Pneumology, INSERM, Paris, France.
Stephane EderhySorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Cardiology, INSERM, Paris, France.
Olivier BenvenisteSorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Clinical Immunology and Internal Medicine, INSERM U974, Paris, France.
Joe-Elie SalemSorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Pharmacology, INSERM, Paris, France.
Yves AllenbachSorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Clinical Immunology and Internal Medicine, INSERM U974, Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Immune checkpoint inhibitors (ICIs) may induce overlapping myositis/myasthenia gravis (MG) features, sparking current debate about pathophysiology and management of this emerging disease entity. We aimed to clarify whether ICI-induced (ir-) myositis and ir-MG represent distinct diseases or exist concurrently. Methods: We performed a retrospective multicenter cohort study. Using the Paris University Hospitals database (n = 2,910,417), we screened all patients with International Classification of Diseases codes or free text related to myositis/MG signs and ICI (n = 620). 'Ir-MG signs' were defined by fatigability, repetitive nerve stimulation (RNS) decrement, and/or acetylcholine receptor antibodies (AChR Abs). Findings: Ir-MG signs were never observed in the absence of ir-myositis (pathological diagnosis (n = 12/14) or CK levels >8000 U/L (n = 2/14)). Among ir-myositis patients, fatigability (2%; n = 1/62) and RNS decrement (2%; n = 1/41) were demonstrated only in one patient with pre-existing MG. AChR Abs testing yielded positive results in 26% of ir-myositis patients (n = 14/53). We revealed that test results were already positive prior to ICI therapy (n = 8/9). Clinically, ir-myositis frequently presented with "MG-like" oculomotor disease (50%; n = 31/62), bulbar dysfunction affecting speech (29%; n = 18/62) and swallowing (42%; n = 26/62), and respiratory disorders (53%; n = 33/62). Extraocular and diaphragm muscles necropsies disclosed intense muscle inflammation (100%; n = 5/5). Interpretation: In our extensive database, we found no evidence of isolated ir-MG, nor of clear neuromuscular junction dysfunction in ir-myositis. These findings suggest that patients with ir-MG suspicion frequently have ir-myositis and ir-MG might be rare. "MG-like" symptoms may stem from ir-myositis-specific predilection for oculo-bulbo-respiratory musculature. Indeed, we revealed florid inflammatory infiltration of the oculomotor and respiratory muscles. Additional studies are needed to confirm these results and to elucidate the role of pre-existing AChR Abs in ir-myositis. Funding: None.

Indexed as

Acetylcholine receptor antibodiesAutoimmunityBiomarkerImmune checkpoint inhibitorImmune checkpoint inhibitor-induced myasthenia gravisImmune checkpoint inhibitor-induced myositisImmune-related adverse eventImmunotherapyMyasthenia gravisMyositis

Identifiers

PMID39896961
PMCPMC11782875

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.